Published Research & Science Studies
Review the peer-reviewed publications and research papers examining the scientific foundation of the NAP™ and PEMF technologies utilized in the NeuroRester system.
Novel non-pharmacological insomnia treatment – a pilot study
Study Design: A prospective pilot study examining the effects of the underlying device (BioBoosti, a previous-generation form factor) on sleep, in 20 adults over 2 weeks.
Important Note: This is an early-stage pilot study (small sample, no placebo control) of the underlying technology, not NeuroRester products. As the authors state, "larger placebo-controlled studies are needed to fully assess efficacy." Provided for reference only; it does not establish the performance of any NeuroRester product. NeuroRester is a general wellness product and is not intended to diagnose, treat, cure, or prevent any disease, including insomnia.
Impact of pulsed electromagnetic field therapy on vascular function and blood pressure in hypertensive individuals
Study Design: A 12-week, controlled study of the underlying PEMF technology in a previous-generation form factor, examining vascular function and blood pressure (N=30 enrolled).
Important Note: This publication examined the underlying technology, not NeuroRester products. Provided for reference only; it does not establish the performance of any NeuroRester product. NeuroRester is a general wellness product and is not intended to diagnose, treat, cure, or prevent any disease.
Funding: Biomobie Regenerative Medicine (Shanghai, China). It is clarified that the sponsor did not involve in the conduct of the study, analysis of the data, interpretation of the data, and drafting, editing, and approving the manuscript.
The impact of pulsed electromagnetic field therapy on blood pressure and circulating nitric oxide levels: a double blind, randomized study in subjects with metabolic syndrome
Study Design: A 12-week, double-blind, randomized, sham-controlled study of the underlying PEMF technology in a previous-generation form factor (N=44).
Important Note: This publication examined the underlying technology, not NeuroRester products. Provided for reference only; it does not establish the performance of any NeuroRester product. NeuroRester is a general wellness product and is not intended to diagnose, treat, cure, or prevent any disease.
Funding: Study funded by Biomobie Regenerative Medicine; authors reported no personal financial interests in the research.
Regulatory References & Disclaimers
References & Disclaimers
References:
[1] Kim CH et al. Blood Pressure, 2019. DOI: 10.1080/08037051.2019.1649591
[2] Stewart GM et al. J Clin Hypertens, 2020. DOI: 10.1111/jch.13877
(Mayo Clinic study funded by Biomobie Regenerative Medicine, Shanghai, China; authors reported no personal financial interests in the research.)
About NeuroRester Corp. R&D by Biomobie, with studies conducted at Mayo Clinic, NeuroRester is the pioneer of the Wellness 2.0 era. We own the exclusive BioBoosti™ and NAP™ technologies, dedicated to supporting human physiological wellness through non-invasive means.
Disclaimer: NeuroRester is a premium health and wellness lifestyle device. It is not a medical device and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. The statements in this document have not been evaluated by the Food and Drug Administration. NeuroRester should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have a medical condition or are taking medication, consult a qualified healthcare provider before use. Individual results will vary.